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Abstract
Background—Clinical prediction rules do not incorporate real time incidence data to adjust
estimates of disease risk in symptomatic patients.
Objective—To measure the value of integrating local incidence data into a clinical decision rule
for diagnosing group A streptococcal (GAS) pharyngitis in patients age 15 years and older.
Design—Retrospective analysis of clinical and biosurveillance predictors of GAS pharyngitis.
Setting—Large U.S.-based retail-health chain.
Patients—82,062 patient visits for pharyngitis.
Measurements—Accuracy of the Centor score, was compared with that of a biosurveillance-
responsive score, essentially an adjusted Centor score based on real-time GAS pharyngitis
information from the 14 days prior to a patient’s visit – the recent local proportion positive
(RLPP).
Results—Increased RLPP correlated with likelihood of GAS pharyngitis (r2 =0.79, p<0.001).
Local incidence data enhanced diagnostic models. For example, when RLPP >0.30, managing
patients with Centor scores of 1 as if scores were 2 would identify 62,537 previously missed
patients annually while misclassifying 18,446 patients without GAS pharyngitis. Decreasing the
score of patients with Centor values of 3 by one point for RLPP <0.20, would spare unnecessary
antibiotics for 166,616 patients while missing 18,812 true positives.
Limitations—Analyses were conducted retrospectively. Real time regional GAS pharyngitis data
are generally not yet available to clinicians.
Conclusions—Incorporating live biosurveillance data into clinical guidelines for GAS
pharyngitis and other communicable diseases should be considered to reduce missed cases when
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the contemporaneous incidence is elevated and spare unnecessary antibiotics when the
contemporaneous incidence is low. Delivering epidemiologic data to the point of care will enable
the use of real-time pre-test probabilities in medical decision-making.
Primary Funding Source—The Mentored Public Health Research Scientist Development
Award K01 HK000055 from the Centers for Disease Control and Prevention and R01 LM007677
from the National Library of Medicine, National Institutes of Health.
Introduction
For communicable diseases, the risk of infection depends on local incidence (1, 2).
However, clinicians rarely can access those data at the point of care and do not use formal
quantitative approaches to adjust estimates of disease probability based on local incidence
(3). The maturation of real-time infectious disease surveillance systems (3–7), coupled with
the increased adoption of electronic health records, offers opportunities to improve clinical
decision-making by incorporating up-to-date information about local disease incidence into
decision support algorithms. Even for diseases like influenza where robust surveillance
exists and results are widely publicized, there are no quantitative, automated methods to
adjust decision support with real-time incidence data (8). Here we evaluate use of real-time
biosurveillance data for management of adults and older adolescents with pharyngitis.
Group A Streptococcus (GAS) is the most common bacterial agent causing acute
pharyngitis, with 600 million cases occurring annually worldwide (9). The disease occurs
across the age spectrum, with a peak incidence in school-age children (5 to 15 years).
Timely antibiotic treatment reduces acute rheumatic fever, suppurative complications,
symptom duration, missed work and school days, and transmission (10). Because physical
examination is an unreliable method to diagnose GAS pharyngitis, the American College of
Physicians (ACP) and the Centers for Disease Control and Prevention (CDC) advocate using
the Centor score to classify GAS pharyngitis risk in adults (11, 12). Clinicians assign the
Centor score (0–4) with one point each for presence of exudates, history of fever, presence
of swollen anterior cervical lymph nodes, and absence of cough. Despite evidence-based
guidelines patients with pharyngitis are often misclassified, leading to inappropriate
antibiotics for those with viral disease and under-treatment of those with bona fide GAS
pharyngitis. The empiric strategy proposed by the ACP leads, in some cases to unnecessary
antibiotics (13, 14), contributing to antimicrobial resistance.
GAS pharyngitis occurs sporadically, with spatial and temporal fluctuations in incidence and
occasional outbreaks (15–18), reflecting a dynamic epidemiology of causative strains (19).
Even when guidelines are followed, the accuracy of rapid GAS pharyngitis testing is
affected by the pre-test probability of disease, which is related to the likelihood of exposure.
In temperate climates, GAS pharyngitis may peak in the winter and early spring (16), but
clinicians currently lack accurate methods to recognize the onset, duration, or magnitude of
local outbreaks from year to year. Here we compare the diagnostic accuracy of the Centor
score adjusted with real-time contemporaneous local disease incidence (biosurveillance)
data vs. the Centor score alone to identify GAS pharyngitis. We limited the clinical analysis
to patients age 15 years and older, for whom the Centor score and ACP guidelines are
intended.
Methods
Participants and Setting
We retrospectively analyzed data collected from patients tested for GAS pharyngitis when
they presented with pharyngitis to MinuteClinic, a large, national retail health chain with
over 500 sites in 26 states (20–23). MinuteClinic provided data for the following time
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periods: October 1, 2006 – February 6, 2008 and August 14, 2008 – October 31, 2008.
Patients were included if they presented with a primary complaint of pharyngitis and were
tested for GAS pharyngitis, or if they had symptoms of pharyngitis and were tested for GAS
pharyngitis. MinuteClinic practice is to care only for non-septic appearing patients. Patients
could contribute more than one encounter. We did not exclude patients who were pregnant,
known to have been treated for streptococcal pharyngitis in the prior month, already on
antibiotics or had co-morbid diseases. Nurse practitioners or physician assistants routinely
collected a consistent set of historical and physical exam elements stored in a common
database across all locations. These providers have demonstrated over 99% adherence to an
established acute pharyngitis protocol – the “Strep Pharyngitis Algorithm” from the Institute
for Clinical Systems Improvement (24); providers collect structured data on signs and
symptoms, obtain rapid GAS pharyngitis tests for all pharyngitis patients (with confirmatory
testing for those who test negative) and treat only those testing positive. The data set was
limited to patients with complete information for the following variables: visit date,
MinuteClinic location, age, signs and symptoms included in the Centor score, and test
results.
Test Methods
All sites used the CLIA (Clinical Laboratory Improvement Amendments)-waived QuickVue
InLine Strep A test (Quidel Corporation, San Diego, CA). The confirmatory test was either a
throat culture (42%) or strep DNA probe (58%). Patients were considered GAS pharyngitis
positive if either the rapid or confirmatory test was positive (25).
Statistical Analysis
Statistical analysis was restricted to the nine MinuteClinic markets with at least 7,000
patient visits each for pharyngitis over the study period, encompassing 132,821 patient
encounters across six states (Georgia, Indiana, Maryland, Minnesota, North Carolina and
Tennessee). For clinical analyses, we included visits from patients at least 15 years old
(n=82,062) with two-thirds (n=54,981) selected randomly for derivation and the rest
(n=27,081) for validation. We included data from patients younger than age 15 years
(n=50,759) when calculating the overall local incidence data, because they contribute to the
epidemiologic context of the clinically analyzed population.
To enable integration of contemporaneous, local GAS pharyngitis epidemiologic data, we
created a biosurveillance variable reflecting disease incidence called recent local proportion
positive (RLPP), a moving window defined as:
To calculate the 14-day RLPP for a patient seen on October 15, 2007, for example, we
divided the number of positive GAS pharyngitis tests by the number of GAS pharyngitis
tests sent in that market from October 1–14, 2007. We calculated 3, 7 and 14-day RLPPs
and compared them using Pearson’s correlation coefficients.
Patients were grouped by Centor score (0–4) and RLPP (in intervals of 0.01). For example,
we calculated the proportion of patients with a Centor score of 2 who tested GAS
pharyngitis positive when the RLPP was 0.30. We performed this calculation for all
combinations of Centor scores (0–4) and RLPP (0.10–0.40) when at least 40 patients shared
a combination. For each Centor score, we plotted the proportion of patients testing positive
as a function of RLPP. Linear regression was used to determine the strength of association
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between the RLPP and GAS pharyngitis positivity for each Centor score, and Pearson
coefficient was used for correlation.
We considered the ACP guideline recommending those with a score of 1 should neither be
tested nor treated for GAS pharyngitis, those with a score of 2 should be tested and treated
only if they test positive, and those with a score of 3 should be treated empirically (one of
two ACP options). For patients with a Centor score of 1 or 2, we evaluated a
biosurveillance-responsive score constructed by adding a point to the score of patients when
the RLPP exceeded the following thresholds: 0.20, 0.25, 0.30, and 0.35. When the RLPP
exceeded the threshold and triggered an increase in the score, we calculated the number of
patients in that group (n) who would be correctly and incorrectly reclassified as GAS
pharyngitis positive. The assumption is that testing is 80% sensitive and 95% specific (26).
We subtracted the number incorrectly reclassified from the number correctly reclassified to
determine the net reclassification, and divided it by the number of patients (n) to determine
the net percent reclassification at each RLPP threshold. To facilitate comparison across the
different RLPP thresholds, we calculated the number of patients reclassified correctly and
incorrectly for hypothetical cohorts of 1000 patients. To determine the number needed to
test to identify each additional case of GAS pharyngitis, we divided the additional number of
patients tested by the additional number correctly reclassified as GAS pharyngitis positive at
each threshold.
We calculated national estimates of the number of patients where management would have
been different when using the biosurveillance-responsive approach compared to the
traditional Centor score approach. To calculate the national impact on an estimated 10.5
million annual national pharyngitis visits (27), we extrapolated the relevant distributions
from the MinuteClinic data for age (62% were 15 years or older), Centor score (i.e. 32% of
patients had a Centor score of 1) and RLPP (i.e. 21% of patients presented when the RLPP
exceeded 0.30). We examined the effect of reducing the score by one for those with a Centor
score of 2 or 3 if the RLPP was below the following thresholds: 0.15, 0.20, and 0.25. We
calculated the number of patients and number per 1000 correctly and incorrectly reclassified
as GAS pharyngitis negative, the net number and net percent reclassified, and the estimated
number of patients nationally whose management would have been altered. The Children’s
Hospital Boston Committee on Clinical Investigation approved this database analysis. We
performed statistical analyses using JMP software, version 8 (SAS Institute, Cary, North
Carolina).
Role of the Funding Source
This work was supported by the Centers for Disease Control and Prevention, and by the
National Library of Medicine, National Institutes of Health. Only the authors had a role in
the study design, data analysis, data interpretation, writing of the manuscript, and the
decision to submit this manuscript for publication.
Results
Table 1 shows patient characteristics for the derivation set (n=54,981), including distribution
by gender, age, clinical findings and Centor score. Two-thirds of patients had Centor scores
of 1–2, and 68% of patients were female. Thirteen percent of the patients were 15–18 years
old. Most patients (91%) had a single encounter, and seven percent had two encounters. In
the validation set, the distribution of patients was the same as in the derivation set for age,
gender, presence of fever, presence of swollen anterior cervical nodes, absence of cough,
presence of tonsillar exudates, and distribution of Centor score. A median number of 7,289
patients were tested per month (IQ range 4365–8602). With regard to volume over time,
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29,826 patients were tested in the first quarter of the study, 32,143 in the second, 36,156 in
the third, and 34,696 in the fourth. The number of patient-visits, n, for the entire study
population were: Georgia 1 (n=7777), Georgia 2 (n=9797), Maryland (n=9720), North
Carolina 1 (n=12,236), Indiana (n=8901), Tennessee (n=15,365), North Carolina 2
(n=10,122), Minnesota 1 (n=30,391), and Minnesota 2 (n=27,972).
The proportion of all patients testing positive varied across time and location, demonstrating
no obvious predictable GAS pharyngitis season (Figure 1). For example, during the week of
December 24, 2007, the proportion positive in three markets was below 20%, in four was
20–29%, and in two was above 30%. Three, seven, and 14-day RLPPs were strongly
correlated (14 vs 7: r2= 0.79, p<0.001, 7 vs 3: r2=0.63, p < 0.001, 14 vs 3, r2= 0.48,
p<0.001), so we used 14-day RLPP for subsequent analyses because it provides a realistic
time frame to generate reliable, contemporaneous local GAS pharyngitis data.
Overall, 25% of all patients tested GAS pharyngitis positive in the derivation and validation
sets, higher than the 17% in the original Centor study, but comparable to Wigton’s
validation study (26%) (11, 28). For patients with Centor scores 1–4, the proportion testing
positive is lowest when the RLPP is low, and increases with rising RLPP (p values for
slopes <0.001). Figure 2 illustrates the proportion testing positive plotted by RLPP, grouped
by Centor score. Each point on the graph represents a group of patients with an identical
Centor score/RLPP dyad. Overall, a patient with a Centor score of 3 is more likely than a
patient with a Centor score of 2 to test GAS pharyngitis positive (43% – 25%), but this
changes under particular epidemiologic conditions. To illustrate, 350/1053 (33%, 95% CI
30%–36%) patients with a Centor score of 2 test positive when the RLPP is above 0.35,
compared to 109/328 (33%, 28%–38%) with a Centor score of 3 when the RLPP is less than
0.15. Figure 3 (see Appendix) shows a similar graphical distribution for the same analysis
using the validation set.
We measured the impact of adding one point to a Centor score of 1 when the RLPP
exceeded specific thresholds. Hypothetically, testing 1000 patients when the RLPP is > 0.30,
for example, would correctly reclassify 139 and incorrectly reclassify 41 patients as positive,
a ratio exceeding 3:1 (Table 2).
By extrapolation, we estimated that approximately 449,908 of the 10.5 million pharyngitis
visits per year, would occur among those 15 years or older, with a Centor score of 1 when
the RLPP exceeded 0.30. The biosurveillance approach to guide management of these
patients would identify 62,537 additional GAS pharyngitis cases in the U.S. annually, while
treating an additional 18,446 patients without GAS pharyngitis. The number needed to test
to detect each additional case of GAS pharyngitis is 7.2. Table 4 (see appendix) displays the
corresponding analyses for the validation set: 60,048 additional cases would be identified,
while 18,103 patients without GAS pharyngitis would be treated. In the validation set, the
number needed to test is 7.4.
We examined outcomes generated by adding one point to the Centor score of adults and
older adolescents with a score of 2 (n=18,942) at specific RLPP cutoffs (Table 2).
Incrementing the score when the RLPP >0.30 and empirically treating a simulated cohort of
1000 of these patients would correctly reclassify 62 but incorrectly reclassify 657 patients as
positive. Extrapolating, this approach correctly identifies 29,450 additional GAS pharyngitis
cases in the U.S. annually, but at a cost of inappropriately treating 312,077 patients without
GAS pharyngitis.
Next, we tabulated outcomes generated by subtracting one point from the Centor score of all
adults and older adolescents with a score of 3 (n=10,056) or 2 (n=18,942) at defined RLPP
cutoffs (Table 3). Testing 1000 hypothetical patients with a score of 3 when the RLPP <
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0.20, rather than treating them empirically would correctly reclassify 620 but incorrectly
reclassify 70 patients as negative. In the U.S., this could spare antibiotics for 166,616
patients (5 million doses) while missing only 18,812 cases annually. Table 5 (appendix)
shows the corresponding data from the validation set: 169,637 patients would be spared
antibiotics, while 17,632 patients would be missed.
Discussion
We asked the question, “What if clinicians could integrate real-time incidence data into
clinical decision-making for patients?” Retail health data on pharyngitis were ideal to
address this question because clinical scores have been validated to estimate GAS
pharyngitis risk in adults, the disease is common, there is temporal and spatial variability in
disease incidence, and by MinuteClinic protocol, all pharyngitis patients undergo GAS
pharyngitis testing, regardless of Centor score. We show that contextualizing the Centor
score, using biosurveillance data to calculate the RLPP, improves prediction of GAS
pharyngitis positivity in patients presenting with pharyngitis, across all clinical risk
categories, and is especially important when the RLPP is at the extremes (high or low). For
adults and older adolescents, adjusting management based on a biosurveillance approach
could improve health outcomes and efficiency of health care delivery.
The ACP/CDC recommends that adults unlikely to have GAS pharyngitis (Centor 0 or 1)
should neither be tested nor treated. We show that adults and older adolescents with a
Centor score of 0 are unlikely to have GAS pharyngitis regardless of RLPP; even when the
RLPP is elevated, their risk of GAS pharyngitis rarely exceeds 15%. However, our data
suggest that during times of elevated RLPP, clinicians should consider testing adults and
older adolescents with a Centor score of 1. Adding a point for adults and older adolescents
with a Centor score of 1 offers greater overall benefit than adding a point to those with a
score of 2. Also, subtracting one point from a score of 3 when the RLPP is low, on balance
spares unnecessary empiric antibiotic therapy with a small reduction in case identification.
Practice guidelines traditionally account for clinical features, and to some extent seasonality,
without regard for real-time epidemiological disease incidence data. Some clinicians
informally incorporate epidemiologic incidence data into their heuristics for medical
decision making, but a clinician’s knowledge of current disease trends may be prejudiced by
recent or unusual cases, leading to cognitive bias and over- or under-estimation of the true
incidence of disease (29, 30). The propagation of retail health clinics in geographically
diverse areas provided an opportunity to evaluate how local incidence data collected via an
unbiased robust, uniform information system can improve clinical decision making.
Developing formal guidelines for incorporating biosurveillance data into the diagnostic and
treatment algorithms for GAS pharyngitis, necessitates a discussion of the relative tradeoffs
between missed cases and over-treatment of those without true bacterial infection. In one
example, increasing the Centor score by one would have resulted in 3.4 additional cases of
GAS pharyngitis diagnosed for every additional negative treated. Nevertheless, the public
health concern of antibiotic resistance must be weighed against the benefits of preventing
complications and morbidities from missed cases.
Limitations
Patients presenting to retail health clinics may be less acutely ill and have fewer co-
morbidities than patients with pharyngitis who present to other types of health care settings,
and our findings should not be applied to individuals suspected of having sepsis. Further,
though all clinical and laboratory data were collected prospectively, the analyses were
conducted retrospectively. There are logistical considerations when integrating the RLPP
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into a clinical decision support framework. The RLPP surveillance signal stream would
weaken if clinicians tested fewer low-risk patients when the RLPP is low. To preserve the
accuracy of the RLPP metric, it would be imperative to maintain a stream of data through
the random, intentional testing of a threshold sample of patients weekly, regardless of
Centor score and RLPP. This testing approach could provide value in disease management
from the population health perspective.
Our data are not able to inform the debate about the importance of the streptococcal carrier
state because serologic tests for GAS pharyngitis were not performed. In this analysis, all
patients were symptomatic with pharyngitis, and this clinical presentation coupled with
positive GAS pharyngitis testing is universally approached as true infection in clinical
practice and decision-making algorithms. We did not have information about family or close
contacts that tested positive for GAS pharyngitis, but we expect that clinicians would
continue to consider this information, if available. Our analyses did not cover all regions of
the country, but did include six different states.
While very large sample size is a strength of our study, the dependence on multiple
providers’ clinical assessments may introduce some variability. However, all information
was collected by NPs and PAs trained to evaluate pharyngitis according to a strict,
computer-driven protocol. Data were not available to permit calculation of intra- or inter-
observer variation in the collection of clinical findings that contribute to the Centor score.
We are limited by the absence of data about locations of patients’ schools or jobs that might
permit more refined epidemiologic modeling. Studies have shown GAS pharyngitis
outbreaks differentially infecting students at different schools within a town (31). Despite
these limitations, we felt that pharyngitis retail health data provided the best available data to
address the question of whether local incidence could help improve management for
symptomatic patients.
Conclusions
Since GAS pharyngitis occurs throughout the calendar year, live biosurveillance becomes
particularly helpful. And since GAS pharyngitis is a common condition affecting millions
per year in the US alone, small improvements in diagnostic accuracy have substantial
impact. Incorporating real-time, biosurveillance-derived epidemiology into a prediction rule
based on a patient’s signs, symptoms, location and timing of presentation (32–34) suggests
the value of this epidemiological analog to personalized genomic medicine (35), in which
the context, instead of being derived from one’s genes, derives from a quantitative
representation of her epidemiologic milieu.
Developers of future recommendations for managing GAS pharyngitis should consider
incorporating real time epidemiology with clinical factors. This novel approach in clinical
guideline creation could help re-stratify risk for patients when the contemporaneous
incidence of disease is high or very low, improving diagnostic accuracy. While our study
focused on GAS pharyngitis, the results may have broad implications for other
communicable diseases, where real-time biosurveillance data might be used to more
accurately deduce the likelihood that a symptomatic individual has a specific disease.
The massive federal investment in health information technology (36) and the maturation of
real-time biosurveillance systems present new opportunities to apply real-time epidemiology
to individual patients (7). The $48 billion dollar investment is intended to support a
“learning health system”(37) with bidirectional communication between clinical and public
health sites, and delivery of clinical decision support to the point of care. Our findings
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suggest that this learning health system should be capacitated to link live biosurveillance
data with clinical decision-making.
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Appendix
Appendix Figure 3. Proportion of patients in the Validation set (n=27,081) testing positive for
Group A Streptococcal pharyngitis by recent local proportion positive (RLPP) and grouped and
labeled by Centor score
Each line represents patients with the same Centor score across varying RLPP. The numbers
at the far right side of the graph identify the Centor score for each line. The proportion of
patients who tested positive increases both as the clinical score increases, and as the RLPP
increases. Pearson’s coefficient was used to measure strength of correlation. The r2,
representing the proportion of the variation in GAS pharyngitis positivity that can be
attributed to the RLPP, is 0.33, (p=0.012) for Centor 4, 0.70 (p<0.001) for Centor 3, 0.82
(p<0.001) for Centor 2, 0.68 (p<0.001) for Centor 1, and 0.35 (p=0.005) for Centor 0. The
slopes of the lines for Centor 4, 3, 2, 1, and 0 are 0.99, 0.80, 0.75, 0.43 and 0.28. Each data
point represents a median of 140 patients (range 45–555 patients, interquartile range 82–
290).
Appendix – Table 4
Reclassification Accuracy of Adjusted Centor Score Resulting From Incrementing Score by
One Point at Different Thresholds of GAS Pharyngitis Activity (Validation set)
Centor RLPP threshold
Number reclassified GAS
pharyngitis positive
Number reclassified
per 1000
National estimates
of numbers affected
Incorrect Correct Net (%) Incorrect Correct Incorrect Correct
1 >0.20 (n1=8681) 373 974 601 43 112 63,118 164,401
>0.25 (n1=3827) 160 504 344 42 132 39,543 124,277
>0.30 (n1=1734) 72 236 164 41 136 18,103 60,048
>0.35 (n1=633) 26 91 65 (10) 41 144 7171 25,186
2 >0.20 (n2=9378) 9738 747 −8990 (−64) 710 50 1,125,725 79,276
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Centor RLPP threshold
Number reclassified GAS
pharyngitis positive
Number reclassified
per 1000
National estimates
of numbers affected
Incorrect Correct Net (%) Incorrect Correct Incorrect Correct
>0.25 (n2=4145) 6555 537 −6018 (−63) 657 62 668,146 63,052
>0.30 (n2=1969) 3117 293 −2824 (−60) 635 66 302,485 19,988
>0.35 (n2=772) 1150 122 −1028 (−57) 630 67 119,019 12,658
Adjustment of Centor Score to reclassify risk according to prior probability of disease as inferred by the recent local
proportion positive (RLPP). For patients with a Centor score of 1 or 2, the score was incremented by one when RLPP
exceeded thresholds. Changing from 1 to 2 would result in testing n1 patients for GAS pharyngitis, and changing from 2 to
3 would result in treating n2 patients empirically. Net change (correct minus incorrect) and net percent change are shown.
The number reclassified correctly and incorrectly standardized per 1000 patients, and the national estimates of the numbers
affected are shown.
Appendix Table 5
Reclassification Accuracy of Adjusted Centor Score Resulting From Decreasing Score by
One Point at Different Thresholds of GAS Pharyngitis Activity (Validation set)
Centor RLPP threshold
Number reclassified GAS
pharyngitis negative
Number reclassified
per 1000
National estimates
of numbers affected
Incorrect Correct Net (%) Incorrect Correct Incorrect Correct
2 RLPP< 0.25 (n2=4395) 722 175 −548 (−12) 164 40 169,260 41,283
RLPP <0.20 (n2=2179) 330 88 −242 (−11) 152 41 75,765 20,436
RLPP < 0.15 (n2=388) 49 16 −33 (−8) 126 42 11,391 3797
3 RLPP < 0.25
(n3=2169)
165 1275 1110 76 588 42,039 325,246
RLPP < 0.20
(n3=1044)
69 663 594 (57) 66 635 17,632 169,637
RLPP < 0.15 (n3=201) 12 134 122 (61) 60 666 2907 32,268
Adjustment of Centor Score to reclassify risk according to prior probability of disease as inferred by the recent local
proportion positive (RLPP). For patients with a Centor score of 2 or 3, the score was decreased by one when RLPP was
below thresholds. Changing from 2 to 1 would result in not testing or treating n2 patients for GAS pharyngitis, and
changing from 3 to 2 would result in testing n3 patients and treating them if they tested positive. Net change (correct minus
incorrect) and net percent change are shown. The number reclassified correctly and incorrectly standardized per 1000
patients, and the national estimates of the numbers affected are shown.
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Figure 1. Proportion positive by study week for nine different locations
The x axis is the study week from January 1, 2007– December 31, 2007, and the y axis is
weekly proportion positive for group A streptococcal pharyngitis. Each graph shows the
proportion of patients who tested positive each week in one of nine markets. The axes have
been standardized to allow comparison across markets. The horizontal line is the average
across all markets (0.25), and is provided for reference and to facilitate comparison.
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Figure 2. Proportion of patients testing positive for Group A Streptococcal pharyngitis by recent
local proportion positive (RLPP) and grouped and labeled by Centor score
Each line represents patients with the same Centor score across varying RLPP. The numbers
at the far right side of the graph identify the Centor score for each line. The proportion of
patients who tested positive increases both as the clinical score increases, and as the RLPP
increases. Pearson’s coefficient was used to measure strength of correlation. The r2,
representing the proportion of the variation in GAS pharyngitis positivity that can be
attributed to the RLPP, is 0.81, (p<0.001) for Centor 4, 0.86 (p<0.001) for Centor 3, 0.86
(p<0.001) for Centor 2, 0.70 (p<0.001) for Centor 1, and 0.47 (p<0.001) for Centor 0. The
slopes of the lines for Centor 4, 3, 2, 1, and 0 are 1.21, 0.88, 0.64, 0.37 and 0.29. Each data
point represents a median of 223 patients (range 41–1152 patients, interquartile range 115–
518).
Fine et al. Page 13
Ann Intern Med. Author manuscript; available in PMC 2013 May 12.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fine et al. Page 14
Table 1
Clinical characteristics of patients presenting with pharyngitis to the retail health clinics (derivation set:
n=54,981 patient-visits)
Characteristic Overall (n=54,981) Group A Streptococcal positive
(n=13,823)
Group A Streptococcal negative
(n=41,158)
Female (%) 68 66 68
Mean age in years (Median, IQ range) 33.5 (33, 24–41) 33.2 (33, 25–40) 33.5 (33, 24–41)
Age group (%)
15–18 years 13 10 14
19–39 years 58 64 56
40–59 years 26 24 26
>60 years 3 2 3
Fever (%) 31 45 26
Swollen anterior cervical lymph nodes (%) 61 77 55
Absence of cough (%) 68 76 66
Tonsillar exudates (%) 22 40 16
Distribution by score
Centor 0 (%) 8 3 10
Centor 1 (%) 33 18 38
Centor 2 (%) 34 34 35
Centor 3 (%) 18 31 14
Centor 4 (%) 6 15 3
IQ : interquartile
To calculate the Centor score for a patient who presents with acute pharyngitis, one point is given for each of the following items: presence of
tonsillar exudates, history of fever, presence of swollen anterior cervical lymph nodes, and absence of cough (11).
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